LIXTE Biotechnology Holdings Provides Corporate Update
LIXTE Biotechnology (NASDAQ:LIXT) announced significant corporate developments, including successful completion of two financings totaling $6.5 million and regaining Nasdaq compliance. The company appointed Geordan Pursglove as Chairman and CEO, while former CEO Bas van der Baan transitioned to President and CSO.
The company's proprietary compound LB-100 received validation through findings published in Nature, demonstrating improved survival outcomes in cancer patients with specific mutations. Clinical trials for ovarian and colorectal cancer are ongoing at prestigious institutions including MD Anderson Cancer Center and Northwestern University, with support from GSK and Roche. Additionally, LIXTE launched a new pre-clinical study with the Netherlands Cancer Institute exploring cancer prevention possibilities.
LIXTE Biotechnology (NASDAQ:LIXT) ha comunicato importanti sviluppi societari: ha completato con successo due round di finanziamento per un totale di 6,5 milioni di dollari e ha riacquistato la conformità ai requisiti Nasdaq. L’azienda ha nominato Geordan Pursglove presidente e CEO, mentre l’ex CEO Bas van der Baan è passato al ruolo di presidente e CSO.
Il composto proprietario dell’azienda, LB-100, ha ottenuto ulteriore validazione grazie a risultati pubblicati su Nature che mostrano un miglioramento della sopravvivenza in pazienti affetti da tumori con specifiche mutazioni. Sono in corso studi clinici su tumore ovarico e colorettale presso istituzioni di rilievo come il MD Anderson Cancer Center e la Northwestern University, con il supporto di GSK e Roche. Inoltre, LIXTE ha avviato uno studio preclinico con il Netherlands Cancer Institute per esplorare possibili applicazioni nella prevenzione del cancro.
LIXTE Biotechnology (NASDAQ:LIXT) anunció hitos corporativos relevantes: completó con éxito dos rondas de financiamiento por un total de 6,5 millones de dólares y recuperó el cumplimiento de las normas de Nasdaq. La compañía nombró a Geordan Pursglove presidente y CEO, mientras que el anterior CEO Bas van der Baan asumió el cargo de presidente y CSO.
El compuesto propio de la empresa, LB-100, recibió validación adicional con hallazgos publicados en Nature, que muestran una mejora en la supervivencia de pacientes con cáncer que presentan mutaciones específicas. Se están llevando a cabo ensayos clínicos para cáncer de ovario y colorrectal en centros de prestigio como el MD Anderson Cancer Center y la Northwestern University, con apoyo de GSK y Roche. Además, LIXTE inició un nuevo estudio preclínico con el Netherlands Cancer Institute para investigar posibilidades de prevención del cáncer.
LIXTE Biotechnology (NASDAQ:LIXT)는 두 차례의 자금 조달을 합쳐 650만 달러를 성공적으로 완료하고 나스닥 규정 준수를 회복하는 등 주요 법인 소식을 발표했습니다. 회사는 Geordan Pursglove를 이사회 의장 겸 CEO로 임명했으며, 전 CEO인 Bas van der Baan은 사장 겸 CSO로 자리를 옮겼습니다.
회사의 독점 화합물 LB-100은 Nature에 발표된 연구 결과를 통해 추가 검증을 받았으며, 특정 돌연변이를 가진 암 환자들의 생존율 개선을 보여주었습니다. 난소암 및 대장암 임상시험이 MD Anderson Cancer Center와 Northwestern University 등 유수 기관에서 진행 중이며 GSK와 Roche의 지원을 받고 있습니다. 추가로 LIXTE는 Netherlands Cancer Institute와 함께 암 예방 가능성을 탐구하는 새로운 전임상 연구를 시작했습니다.
LIXTE Biotechnology (NASDAQ:LIXT) a annoncé des développements importants : la clôture réussie de deux financements totalisant 6,5 millions de dollars et le rétablissement de sa conformité au Nasdaq. La société a nommé Geordan Pursglove président et CEO, tandis que l’ancien CEO Bas van der Baan est devenu President et CSO.
Le composé propriétaire de la société, LB-100, a été validé par des résultats publiés dans Nature, montrant une amélioration de la survie chez des patients atteints de cancers avec des mutations spécifiques. Des essais cliniques pour les cancers de l’ovaire et colorectal sont en cours dans des établissements prestigieux tels que le MD Anderson Cancer Center et la Northwestern University, avec le soutien de GSK et Roche. De plus, LIXTE a lancé une nouvelle étude préclinique avec le Netherlands Cancer Institute afin d’explorer des pistes de prévention du cancer.
LIXTE Biotechnology (NASDAQ:LIXT) gab wesentliche Unternehmensentwicklungen bekannt: die erfolgreiche Durchführung von zwei Finanzierungsrunden in Höhe von insgesamt 6,5 Millionen US-Dollar sowie die Wiederherstellung der Nasdaq-Compliance. Das Unternehmen ernannte Geordan Pursglove zum Vorsitzenden und CEO, während der ehemalige CEO Bas van der Baan die Position des President und CSO übernahm.
Die firmeneigene Verbindung LB-100 erhielt zusätzliche Bestätigung durch in Nature veröffentlichte Befunde, die verbesserte Überlebensraten bei Krebspatienten mit bestimmten Mutationen zeigen. Klinische Studien zu Eierstock- und Darmkrebs laufen an renommierten Einrichtungen wie dem MD Anderson Cancer Center und der Northwestern University, mit Unterstützung von GSK und Roche. Zudem startete LIXTE eine neue präklinische Studie mit dem Netherlands Cancer Institute, die Möglichkeiten zur Krebsprävention untersucht.
- None.
- Recent management restructuring may create temporary transition challenges
- Additional funding may be needed for long-term clinical trial completion
Insights
LIXTE secures $6.5M funding, regains Nasdaq compliance, and receives important scientific validation for its LB-100 cancer compound in Nature journal.
LIXTE Biotechnology has executed a strategic turnaround with its recent
The scientific validation published in Nature represents a significant external endorsement of LIXTE's approach. The findings demonstrate that tumors with inactivating mutations in PPP2R1A (the target of LIXTE's LB-100 compound) showed significantly better overall survival with immune checkpoint blockade therapy. This third-party validation substantially strengthens the scientific rationale behind LIXTE's ongoing clinical trials.
The company's ongoing clinical partnerships with prestigious institutions (MD Anderson, Northwestern University) and major pharmaceutical companies (GSK, Roche) provide both credibility and financial support for their development programs. These collaborations reduce LIXTE's cash burn rate while accelerating clinical progress.
The management restructuring brings a strategic shift with Geordan Pursglove assuming the CEO role while former CEO Bas van der Baan transitions to focus on scientific leadership. This reorganization, coupled with the new Scientific Advisory Committee, suggests an increased emphasis on both clinical development and commercialization pathways.
The new pre-clinical study on cancer prevention represents an expansion of LIXTE's potential therapeutic applications, potentially broadening the market opportunity for LB-100 beyond its current focus on treatment. This diversification strategy could enhance long-term value if successful.
-Completes Two Financings, Raising
-Regains Compliance for Continued Listing on Nasdaq-
-Announces Management Changes; Adds Two New Board Members-
-Re-Establishes Scientific Advisory Committee-
-Reports on New Findings Published in Scientific Journal Nature
that Validate LIXTE’s Ongoing Clinical Trials with LB-100-
-Launches New Pre-Clinical Study-
PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities.
“This has been a transformative period for our company,” said Geordan Pursglove, who became LIXTE’s new Chairman and Chief Executive Officer in June. “Momentum has been energized on several fronts, including securing essential funding to support our ongoing clinical trials, and to pursue long-term growth opportunities to enhance shareholder value.”
Added Bas van der Baan, President and Chief Scientific Officer, “We are especially proud of the recent publication in a leading medical journal, Nature, further validating the promise of our proprietary compound, LB-100, to treat ovarian and colorectal cancer. The recent formation of our medical advisory committee marks yet another strategic step toward our mission of developing and delivering effective solutions to patients battling cancer.”
LIXTE’s clinical trials are underway for ovarian cancer at the M.D. Anderson Cancer Center and at Northwestern University, supported by GSK. The Company’s colorectal trial, supported by F. Hoffmann-La Roche, is being conducted at the Netherlands Cancer Institute.
Summary of Recent Corporate Activities:
- Completion of two financings: a private placement with accredited investors, raising aggregate gross proceeds to the Company of approximately
$5 million , and a registered direct offering with accredited investors, raising aggregate gross proceeds to the Company of approximately$1.5 million . Proceeds will be used for general corporate purposes and working capital and allowed the Company to regain compliance for continued listing on the Nasdaq Capital Market.
- Management and Board changes: Geordan Pursglove was appointed Chairman and Chief Executive officer in June 2025, succeeding Bas van der Baan, who became President and Chief Scientific Officer. Jason Sawyer and Michael Holloway, MD, joined LIXTE’s Board as independent directors in July 2025, succeeding Stephen Forman, MD, and Yun Yen, MD, who were appointed to serve as members of a newly established Scientific Advisory Committee. Other committee members include Bas van der Baan and Board member René Bernards, PhD.
- Validation of LB-100: The medical journal Nature has published findings that validate LIXTE’s ongoing clinical trials with LB-100. A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of patients treated with immune checkpoint blockade therapy. The study showed that patients having tumors with inactivating mutations in PPP2R1A - the major scaffold subunit of protein phosphatase 2A (PP2A) - had significantly better overall survival, compared with patients who did not have this mutation in their tumors. (https://www.nature.com/articles/s41586-025-09203-8
- New Pre-Clinical trial: LIXTE has initiated a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether “initiated” cells that carry mutations found in cancer cells can be eliminated by treatment with LB-100. The study represents a new opportunity in cancer prevention.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ
How much funding did LIXTE Biotechnology (LIXT) raise in its recent financings?
Who is the new CEO of LIXTE Biotechnology (LIXT)?
What are the key findings from the Nature publication about LIXTE's LB-100?
Where are LIXTE Biotechnology's clinical trials being conducted?
What is the purpose of LIXTE's new pre-clinical study?
